Key Takeaways
Dr. Reddy's Laboratories (NYSE: RDY) launched its generic Semaglutide injection in Canada just weeks after receiving regulatory approval, making it one of the first to market in a G7 country.
"The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr. Reddy's CEO Erez Israeli said in a statement. "We remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients."
The launch follows a Notice of Compliance from Health Canada on April 28, 2026. The once-weekly injection, indicated for adults with type 2 diabetes mellitus, will be available in 2 mg and 4 mg pre-filled pens. The 2 mg pen delivers doses of 0.25 mg or 0.5 mg, while the 4 mg pen delivers 1 mg doses.
The introduction of a generic version is expected to increase competition and lower prices in Canada's growing market for GLP-1 therapies, currently dominated by Novo Nordisk. For Dr. Reddy's, this opens a significant new revenue stream, building on its recent launch of the drug in India under the brand name Obeda.
The therapy is designed to improve glycemic control in combination with diet and exercise. Dr. Reddy's specified the drug is not intended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis and should not be used as a substitute for insulin.
"As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets," Israeli added. The global market for Semaglutide is experiencing surging demand due to its effectiveness in managing diabetes and its increasing use for weight management.
The successful launch in a G7 nation positions Dr. Reddy's as a key player in the global generic GLP-1 market. Investors will now watch for the company's market share capture in Canada and any announcements of filings in other major markets.
This article is for informational purposes only and does not constitute investment advice.
